Forest Laboratories "buy"

01/15/07 - Lazard Capital Markets

NEW YORK, January 15 (newratings.com) - Analysts at Lazard Capital reiterate their "buy" rating on Forest Laboratories (FRX). The target price is set to $60.

In a research note published on January 12, the analysts mention that the company is likely to have generated 16% y/y EPS growth and 12% y/y revenue growth in F3Q. The prescription trends for Namenda and Lexapro are likely to have been robust during the quarter, the analysts add.